Effect of dexmedetomidine on acute kidney injury after cardiac valve replacement
Objective To study the effect of dexmedetomidine on acute kidney injury (AKI) after cardi-ac valve replacement.Methods A retrospective analysis was performed on 183 patients who underwent cardi-ac valve replacement under cardiopulmonary bypass in the hospital from January 2022 to March 2023.Among them,59 patients received continuous dexmedetomidine treatment for more than 24 hours,which was defined as the observation group;and 124 patients did not receive dexmedetomidine treatment,which was defined as the control group.The perioperative indexes of the two groups were compared.Results There was no signifi-cant difference in clinical baseline characteristics between the two groups (P>0.05).Compared with the con-trol group,the incidence of postoperative AKI in the observation group was lower,the ICU stay time was shorter,and the difference was statistically significant (P<0.05).There was no significant difference between the two groups in continuous renal replacement therapy,mechanical ventilation,pulmonary infection,arrhyth-mia and secondary thoracotomy (P>0.05).Logistic regression analysis showed that dexmedetomidine was a protective factor for postoperative AKI (OR=0.207,95％CI:0.060-0.718,P=0.013).Conclusion Dexme-detomidine can reduce the incidence of AKI and shorten the ICU stay after cardiac valve replacement.
万方数据
维普
